885520-23-0

Basic information

• Product Name: 6-BROMO-4-FLUORO-1H-INDAZOLE
• Synonyms: 6-bromo-4-fluoro-1H-indazole
• CAS NO: 885520-23-0
• Molecular Formula: C₇H₄BrFN₂
• Molecular Weight: 215.03
• Mol File: 885520-23-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 331.275 °C at 760 mmHg
• Flash Point: 154.15 °C
• Appearance: /
• Density: 1.862 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.693
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.00±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-4-FLUORO-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-FLUORO-1H-INDAZOLE(885520-23-0)
• EPA Substance Registry System: 6-BROMO-4-FLUORO-1H-INDAZOLE(885520-23-0)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 885520-23-0(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-fluoro-1H-indazole is a chemical compound with the molecular formula C7H4BrFN2. It is a heterocyclic compound that contains both bromine and fluorine atoms. This indazole derivative is commonly used as a building block in the pharmaceutical industry for the synthesis of various bioactive compounds. Its versatile nature and structural properties make it a valuable tool for medicinal chemistry research. Additionally, this chemical has potential applications in the development of new drug candidates for various therapeutic targets.

InChI:InChI=1/C7H4BrFN2/c8-4-1-6(9)5-3-10-11-7(5)2-4/h1-3H,(H,10,11)

Upstream product

• 461-96-1 3,5-difluorobromobenzene 
• 886761-86-0 5-bromo-3-fluoro-2-methyl-phenylamine 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 1227912-19-7 6-bromo-4-fluoro-1H-indazol-3-amine 
• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 

Downstream Products

• 937047-78-4 6-bromo-2-(cyclohexylmethyl)-2H-indazole 
• 937047-77-3 2-benzyl-6-bromo-4-fluoro-2H-indazole 
• 1562195-50-9 (1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-3-iodo-1H-indazol-6-yl)(3-methoxyazetidin-1-yl)methanone 
• 1562195-54-3 methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-6-(3-methoxyazetidine-1-carbonyl)-1H-indazol-3-yl)-5-fluoro-2-methoxybenzoate 
• 1562195-58-7 methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-6-(3-methoxyazetidine-1-carbonyl)-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoate 
• 1562397-95-8 4-(1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-6-(3-methoxyazetidine-1-carbonyl)-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoic acid 
• 1562194-20-0 sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-6-(3-methoxyazetidine-1-carbonyl)-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoate 
• 885521-35-7 methyl 4-fluoro-3-iodo-1H-indazole-6-carboxylate 
• 1562194-72-2 methyl 1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-3-iodo-1H-indazole-6-carboxylate 
• 1562194-75-5 1-(2-chloro-6-(trifluoromethyl)benzyl)-4-fluoro-3-iodo-1H-indazole-6-carboxylic acid 
• 885521-44-8 methyl 4-fluoro-1H-indazole-6-carboxylate 

Relevant articles and documents

Aryl imidazole derivative and application thereof

The invention relates to an aryl imidazole derivative and application thereof. The aryl imidazole derivative is a compound shown as a formula (I) in the description or pharmaceutically acceptable salt thereof. The invention also discloses application of the aryl imidazole derivative in preparation of drugs for treating cancers. The invention further discloses application of the aryl imidazole derivative in preparation of drugs for treating diseases caused by EGFR mutation.

Development of a late-stage diversification strategy for the 4- And 5-Positions of 4,5,6-trisubstituted indazoles

Indazoles represent a privileged motif in drug discovery. However, the formation of highly substituted indazoles can require the execution of lengthy synthetic routes with minimal opportunities to introduce diversity. In this report, we disclose the development of a late-stage diversification strategy for the 4- and 5-positions of 4,5,6-trisubstituted indazoles. A regioselective C-H functionalization and subsequent nucleophilic aromatic substitution provide two sequential points of diversification. The synthetic sequence delivers rapid access to an array of 4,5,6-trisubstituted indazoles in only four steps from readily available starting materials.

AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY

An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.